SCHEDULE: Integrated BioPharma: Reporting Group Exits Ownership

The reporting group, including the estate of Carl DeSantis, has ceased beneficial ownership of Integrated BioPharma, Inc. shares.

Summary

• The reporting group, consisting of CD Financial, LLC, CDS Group Holdings, L.L.C., and the estate of Carl DeSantis, has officially exited its position in Integrated BioPharma, Inc.
• As of April 15, 2026, the group holds 0 shares, representing 0.0% of the company's outstanding common stock.
• The exit follows the transfer of all shares to CDDS 2.0, LLC, an entity controlled by Damon DeSantis, following the death of Carl DeSantis.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event reflecting the conclusion of an estate's reporting obligations rather than a change in the company's operational health.

Positives

• The filing provides clear transparency regarding the finalization of the estate's divestment.
• The transition of ownership to a related party (Damon DeSantis) suggests an orderly transfer of assets.

Negatives

• The loss of a long-term reporting shareholder may reduce institutional visibility for the issuer.

Risks

• The issuer may face changes in shareholder composition and potential shifts in strategic influence following the transfer of a significant block of shares to a new entity.

Future Outlook

The reporting group has no present plans or proposals regarding the issuer and has exited its reporting obligations.

Industry Context

StockSavvy.ai notes that this filing represents a standard administrative cleanup following an estate transition, which is common in closely held or family-controlled small-cap entities.

Comparison to Industry Standards

• The filing adheres to standard SEC requirements for reporting the cessation of beneficial ownership under Section 13(d).
• The transition of shares to a successor entity is consistent with typical estate management practices for publicly traded securities.

Legal Proceedings

• None reported.

Related Party Transactions

• The transfer of shares to CDDS 2.0, LLC, an entity controlled by Damon DeSantis, is a related party transaction resulting from the estate of Carl DeSantis.

Stakeholder Impact

• Shareholders should note the shift in beneficial ownership to CDDS 2.0, LLC, which now holds more than 5% of the issuer's stock.

Next Steps

• The reporting group will no longer file reports regarding the issuer.

Key Dates

Keywords

Integrated BioPharma, Schedule 13D, Beneficial Ownership, Divestment, Estate Planning, Carl DeSantis